Opus Genetics, Inc. (IRD)

Opus Genetics, Inc. (NASDAQ:IRD) Receives Consensus Recommendation of “Moderate Buy” from Brokerages

Squarepoint Ops LLC Takes $1.36 Million Position in Opus Genetics, Inc. $IRD

Opus Genetics: A Resounding Study Success Merits A Higher Valuation

Opus Genetics, Inc. (IRD) Discusses Topline Results From Cohort 1 of BEST1 Phase I/II Gene Therapy Trial Transcript

Gene Therapy at Lower Dose Shows Vision Improvements, Opus Genetics Says

Opus Genetics Announces Positive Low Dose Cohort 1 Data from Phase 1/2 Clinical Trial of OPGx-BEST1 and Successful FDA Type C Meeting with Potential Phase 3 Dosing in 2027

Analysts Set Opus Genetics, Inc. (NASDAQ:IRD) PT at $10.69

Opus Genetics to Present OPGx-BEST1 Cohort 1 Clinical Data in Investor Webcast and at Upcoming Leading Ophthalmology Conferences

ADAR1 Capital Management LLC Takes $7.33 Million Position in Opus Genetics, Inc. $IRD

Opus Genetics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Opus Genetics, Inc. (IRD) Reports Q2 Loss, Lags Revenue Estimates

Opus Genetics Completes Patient Enrollment in Registrational Phase 3 Trial of OPGx-LCA5 for LCA5-Associated Inherited Retinal Disease